Program
amivantamab
Also written as “Amivantamab”, “Amivantamab IV” and “Amivantamab SC”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 1512 open or running | phase 3since Jul 23, 2020 | Nov 18, 2015 | Dec 31, 2026phase 1 · NCT02609776 |
| AstraZeneca | 11 open or running | phase 2since Mar 24, 2023 | Mar 24, 2023 | Oct 1, 2027phase 2 · NCT05801029 |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 18, 2015.
- Jul 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04487080 · 1,074 enrolled · United States, Argentina, Australia and more
- Jun 23, 2021Phase 2 study in Stomach NeoplasmsJohnson & Johnson · NCT04945733 · 62 enrolled · Japan
- Jul 30, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04988295 · 776 enrolled · United States, Argentina, Belgium and more
- May 17, 2022Phase 2 study in Colorectal NeoplasmsJohnson & Johnson · NCT05379595 · 225 planned · United States, Belgium, Canada and more
- May 19, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05388669 · 418 enrolled · United States, Argentina, Australia and more
- Aug 3, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05488314 · 57 enrolled · United States, Brazil, Canada and more
- Dec 8, 2022Phase 2 study in Carcinoma, HepatocellularJohnson & Johnson · NCT05653427 · 18 enrolled · China
- Mar 24, 2023AstraZeneca's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT05801029 · 60 enrolled · Hong Kong, Malaysia, Singapore and more
- Nov 2, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06120140 · 305 enrolled · United States, Argentina, Brazil and more
- Apr 23, 2024Phase 2 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT06385080 · 287 planned · United States, China, France and more
- Jul 29, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06532032 · 12 enrolled · United States, Taiwan, Turkey (Türkiye) and more
- Oct 28, 2024Phase 3 study in Colorectal NeoplasmsJohnson & Johnson · NCT06662786 · 1,000 planned · United States, Belgium, Brazil and more
- Dec 20, 2024Phase 3 study in Colorectal NeoplasmsJohnson & Johnson · NCT06750094 · 700 planned · United States, Australia, Belgium and more
- Dec 1, 2025Phase 3 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT07276399 · 600 planned · United States, Australia, Austria and more
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT02609776
- Feb 12, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04077463
- Apr 27, 2027Primary completion: phase 2 study in Colorectal NeoplasmsJohnson & Johnson · NCT05379595
- Apr 28, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05488314
TargetBeta
“A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07276399Squamous Cell Carcinoma of Head and Neck · United States, Australia, Austria and more | 3 | Recruiting | Johnson & Johnson | Jun 18, 2029 | 600 |
| NCT06750094Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Johnson & Johnson | Dec 15, 2027 | 700 |
| NCT06662786Colorectal Neoplasms · United States, Belgium, Brazil and more | 3 | Recruiting | Johnson & Johnson | Dec 15, 2028 | 1,000 |
| NCT06532032Carcinoma, Non-Small-Cell Lung · United States, Taiwan, Turkey (Türkiye) and more | 2 | Completed | Johnson & Johnson | May 14, 2026 | 12 |
| NCT06385080Squamous Cell Carcinoma of Head and Neck · United States, China, France and more | 2 | Recruiting | Johnson & Johnson | Dec 27, 2032 | 287 |
| NCT06120140Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 2 | Active, not recruiting | Johnson & Johnson | May 31, 2027 | 305 |
| NCT05801029Carcinoma, Non-Small-Cell Lung · Hong Kong, Malaysia, Singapore and more | 2 | Active, not recruiting | AstraZeneca | Oct 1, 2027 | 60 |
| NCT05653427Carcinoma, Hepatocellular · China | 2 | Terminated | Johnson & Johnson | Oct 10, 2023 | 18 |
| NCT05488314Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more | 2 | Active, not recruiting | Johnson & Johnson | Apr 28, 2027 | 57 |
| NCT05388669Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Jan 3, 2024 | 418 |
| NCT05379595Colorectal Neoplasms · United States, Belgium, Canada and more | 2 | Recruiting | Johnson & Johnson | Apr 27, 2027 | 225 |
| NCT04988295Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Jul 10, 2023 | 776 |
| NCT04945733Stomach Neoplasms · Japan | 2 | Terminated | Johnson & Johnson | Jul 3, 2023 | 62 |
| NCT04487080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Aug 11, 2023 | 1,074 |
| NCT04077463Carcinoma, Non-Small-Cell Lung · United States, China, France and more | 1 | Active, not recruiting | Johnson & Johnson | Feb 12, 2027 | 701 |
| NCT02609776Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 1 | Active, not recruiting | Johnson & Johnson | Dec 31, 2026 | 751 |
How it is read
Names in the registry
- “Amivantamab”, 15 entries
- “Amivantamab IV”, 2 entries
- “Amivantamab SC”, 1 entry
- “Amivantamab Intravenous”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Colorectal Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Carcinoma, Hepatocellular, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.